Perrot, A., Hulin, C., Harel, S., Vitry, V., Pieragostini, A., Manier, S., Croizier, C., Lenain, P., Gay, J., Frenzel, L., Chalopin, T., Chalayer, E., Chiche, E., Vincent, L., Moreau, S., Macro, M., Montes, L., Chaoui, D., Demarquette, H., Colella, J. M. S. D., Mottier, C. S., Piocelle, F. O., Dorvaux, V., Merzoug, K. B., Roland, V., Fontan, J., Decaux, O., Brieuc, C., Benramdane, R., Breal, C., Arthur, D., Vernet, S., Pierres, M., Petillon, M. O., Moreau, P., Boumendil, A., Touzeau, C. (2025). First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.. Blood. https://doi.org/10.1182/blood-2025-5836